 |
Indication & Dosage |
| |
| |
| Irrigation |
| BREAK DOWN OF CLOTS IN HYPHAEMA |
| Adult:
5000 units dissolved in 2 ml of 0.9% NaCl to be used for irrigation of clots in the anterior chamber. |
| |
| Intravenous |
| PULMONARY EMOBOLISM |
| Adult:
2500 units/ml infused, into a clot via the catheter, at a rate of 4000 units/min. The catheter is advanced into the remaining occlusion every 2 hr until normal flow resumes and is then partially removed and an infusion of 1000 units/min is given until the remaining clot is lysed. |
| |
| Parenteral |
| TREATMENT OF DEEP-VEIN THROMBOSIS |
| Adult:
2500 units/ml infused, into a clot via the catheter, at a rate of 4000 units/min. The catheter is advanced into the remaining occlusion every 2 hr until normal flow resumes and is then partially removed and an infusion of 1000 units/min is given until the remaining clot is lysed. |
| |
| Oral |
| BREAK DOWN OF CLOTS IN HYPHAEMA |
| Adult:
2500 units/ml infused, into a clot via the catheter, at a rate of 4000 units/min. The catheter is advanced into the remaining occlusion every 2 hr until normal flow resumes and is then partially removed and an infusion of 1000 units/min is given until the remaining clot is lysed. |
| |
| Parenteral |
| CLEARANCE OF OCCLUDED CATHETERS AND SHUNTS |
| Adult:
2500 units/ml infused, into a clot via the catheter, at a rate of 4000 units/min. The catheter is advanced into the remaining occlusion every 2 hr until normal flow resumes and is then partially removed and an infusion of 1000 units/min is given until the remaining clot is lysed. |
| |
| Parenteral |
| TREATMENT OF ACUTE MYOCARDIAL INFARCTION |
| Adult:
2500 units/ml infused, into a clot via the catheter, at a rate of 4000 units/min. The catheter is advanced into the remaining occlusion every 2 hr until normal flow resumes and is then partially removed and an infusion of 1000 units/min is given until the remaining clot is lysed. |
|
| |
|
| Precautions |
Any vascular punctures or invasive procedures should be avoided as far as possible during, and immediately before and after urokinase therapy and if unavoidable done with great care. External chest compression. Caution in conditions eg, possibility of left heart thrombus, subacute bacterial endocarditis, coagulation defects, cerebrovascular disease, diabetic retinopathy and any conditions in which bleeding could be dangerous. Monitor for reperfusion arrhythmias when used in MI. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Bleeding, pyrexia, haematuria, thromboembolic episodes, hypersensitivity reactions. |
| |
|
| Adverse Drug Reactions |
Severe bleeding, anaphylaxis. |
| |
|
| Interactions |
Reduced thrombolytic effect when given again some time later due to development of high levels of antibodies. |
| |
|
|
|
